AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9834048 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zaleplon
Number of subjects: 10
Study 9834048 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zaleplon
Number of subjects: 10
Study 9834048 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem
Number of subjects: 10
Study 9834048 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zolpidem
Number of subjects: 10
Study 9834048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8135430 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous cutdown
Number of subjects: 78
Study 8135430 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous femoral line
Number of subjects: 78
Study 2678768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid 3.5‐5.0 hours preoperatively
Number of subjects: 202
Study 2678768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid 0.5‐1.0 hour preoperatively
Number of subjects: 202
Study 2678768 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (5 doses beginning 0.5‐1.0 hour preoperatively)
Number of subjects: 202
Study 264441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed appliances
Number of subjects: 30
Study 264441 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal plates
Number of subjects: 30
Study 264441 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional orthodontics
Number of subjects: 30
Study 264441 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 31574343 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice syrup (5 cc, twice a day for 6 months)
Number of subjects: 39
Study 31574343 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup (5 cc, twice a day for 6 months)
Number of subjects: 39
Study 30612487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for insomnia (CBTi)
Number of subjects: 24
Study 28170357 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower INR goal of 1.5-2.0
Number of subjects: 0
Study 28170357 — intervention group
Group type: COMPARATOR
Intervention: Standard INR goal of 2.5 (range, 2-3)
Number of subjects: 0
Study 26924011 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding
Number of subjects: 120
Study 26924011 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding plus domperidone
Number of subjects: 120
Study 26924011 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule
Number of subjects: 120
Study 25140981 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use in the last year
Number of subjects: 309
Study 25140981 — intervention group
Group type: COMPARATOR
Intervention: Patients who stopped using alcohol in the past year
Number of subjects: 309
Study 25140981 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with last-year alcohol use and past alcohol use disorders
Number of subjects: 309
Study 25140981 — intervention group
Group type: COMPARATOR
Intervention: Patients who stopped using alcohol for at least a year
Number of subjects: 309
Study 22476610 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 60
Study 22476610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19742431 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency revascularization
Number of subjects: 0
Study 19742431 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive therapies
Number of subjects: 0
Study 17617280 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg + valsartan 320 mg
Number of subjects: 3161
Study 17617280 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 3161
Study 17617280 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 3161
Study 17617280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3161
Study 17617280 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg + valsartan 160 mg
Number of subjects: 3161
Study 17617280 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg + valsartan 320 mg
Number of subjects: 3161
Study 17617280 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 3161
Study 17617280 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 3161
Study 17617280 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 20 mg
Number of subjects: 3161
Study 17617280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 3161
Study 17617280 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine monotherapy
Number of subjects: 3161
Study 17617280 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan monotherapy
Number of subjects: 3161
Study 14707154 — intervention group
Group type: COMPARATOR
Intervention: Typical American control diet with higher sodium intake (150 mmol/d)
Number of subjects: 390
Study 14707154 — intervention group
Group type: COMPARATOR
Intervention: Typical American control diet with lower sodium intake (50 mmol/d)
Number of subjects: 390
Study 14707154 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with higher sodium intake (150 mmol/d)
Number of subjects: 390
Study 14707154 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with lower sodium intake (50 mmol/d)
Number of subjects: 390
Study 12611200 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxomemazine with guaifenesin (T)
Number of subjects: 130
Study 12611200 — intervention group
Group type: COMPARATOR
Intervention: Clobutinol (S)
Number of subjects: 130
Study 12611200 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medicines
Number of subjects: 130
Study 10221355 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scales (VAS) of alertness
Number of subjects: 9
Study 10221355 — intervention group
Group type: EXPERIMENTAL
Intervention: Average mood scores
Number of subjects: 9
Study 10221355 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive tracking
Number of subjects: 9
Study 10221355 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic eye movements
Number of subjects: 9
Study 10221355 — intervention group
Group type: EXPERIMENTAL
Intervention: Body sway
Number of subjects: 9
Study 10221355 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG beta2-amplitudes
Number of subjects: 9
Study 10221355 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth pursuit, DSST, and other EEG-amplitudes
Number of subjects: 9
Study 7759712 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal biphasic shocks
Number of subjects: 15
Study 7759712 — intervention group
Group type: COMPARATOR
Intervention: Cathodal biphasic shocks
Number of subjects: 15
Study 7759712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both configurations
Number of subjects: 15
Study 7759712 — intervention group
Group type: COMPARATOR
Intervention: Cathodal configuration
Number of subjects: 15
Study 2155881 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental program consisting of patient teaching via pamphlet and videotape, and regular home visits by a community health nurse.
Number of subjects: 0
Study 2155881 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study 6260260 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MRC unit of pCT in glycine vehicle
Number of subjects: 11
Study 6260260 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 units of pCT in gelatine vehicle
Number of subjects: 11
Study 6260260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31764804 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine treatment group
Number of subjects: 148
Study 31764804 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment group
Number of subjects: 148
Study 29077816 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (chlorophyll flavour, with 2.1 g carbohydrate)
Number of subjects: 20
Study 29077816 — intervention group
Group type: COMPARATOR
Intervention: Control (no gum chewing)
Number of subjects: 20
Study 29077816 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 20
Study 29077816 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 25924880 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (SMK)
Number of subjects: 22
Study 25924880 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers (N‐SMK)
Number of subjects: 22
Study 24580384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided identification of landmarks
Number of subjects: 170
Study 24580384 — intervention group
Group type: COMPARATOR
Intervention: Manual palpation of landmarks
Number of subjects: 170
Study 22530879 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink (1.0 g·kg(‐1) body weight)
Number of subjects: 0
Study 22530879 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric Sucralose sweetened control drink
Number of subjects: 0
Study 22530879 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EXR)
Number of subjects: 0
Study 22530879 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (SED) activity
Number of subjects: 0
Study 19304119 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day enalapril plus 80 mg/day valsartan (combination group)
Number of subjects: 20
Study 19304119 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/day enalapril (control group)
Number of subjects: 20
Study 17805035 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (Fosamax) administered for at least 6 months
Number of subjects: 15
Study 17805035 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (Fosamax)
Number of subjects: 15
Study 15657405 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosing of docetaxel (mean 58.1 mg/m2, range 37.4 to 76.4 mg/m2)
Number of subjects: 59
Study 15657405 — intervention group
Group type: COMPARATOR
Intervention: BSA-based dosing of docetaxel (60 mg/m2)
Number of subjects: 59
Study 15657405 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosing of docetaxel
Number of subjects: 59
Study 15657405 — intervention group
Group type: COMPARATOR
Intervention: BSA-based dosing of docetaxel
Number of subjects: 59
Study 11959402 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk group
Number of subjects: 33
Study 11959402 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 9619472 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise, education, and stress management (EXESM; n = 29)
Number of subjects: 79
Study 9619472 — intervention group
Group type: COMPARATOR
Intervention: Education and stress management (ESM; n = 25)
Number of subjects: 79
Study 9619472 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL; n = 25)
Number of subjects: 79
Study 7622809 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20-60 mg)
Number of subjects: 391
Study 7622809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 1974072 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 25 mg
Number of subjects: 0
Study 1974072 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 50 mg
Number of subjects: 0
Study 1974072 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 100 mg
Number of subjects: 0
Study 1974072 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2 mg (verum)
Number of subjects: 0
Study 1974072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 433668 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 100
Study 433668 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 100
Study 31928032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette responses regarding hiring a health care advocate
Number of subjects: 1862
Study 31928032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette responses regarding hiring a health care advocate for parents
Number of subjects: 1862
Study 30967159 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline plus sodium hyaluronate
Number of subjects: 56
Study 30967159 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 56
Study 26439722 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ingestion of dairy milk with bread
Number of subjects: 12
Study 26439722 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ingestion of soy milk with bread
Number of subjects: 12
Study 26439722 — intervention group
Group type: EXPERIMENTAL
Intervention: Preloading (30 min prior to bread) with either dairy or soy milk
Number of subjects: 12
Study 26439722 — intervention group
Group type: COMPARATOR
Intervention: Reference meal (white wheat bread with water)
Number of subjects: 12
Study 25947329 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH enoxaparin 40 mg subcutaneously once daily plus standard pregnancy surveillance
Number of subjects: 0
Study 25947329 — intervention group
Group type: COMPARATOR
Intervention: Standard pregnancy surveillance alone
Number of subjects: 0
Study 23391727 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural activation (n = 50)
Number of subjects: 100
Study 23391727 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU, antidepressant medication) (n = 50)
Number of subjects: 100
Study 20682020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 106
Study 20682020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 106
Study 20682020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) and Tacrolimus (Tac)
Number of subjects: 106
Study 19766640 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release mesalamine 4.8 g/day
Number of subjects: 772
Study 19766640 — intervention group
Group type: COMPARATOR
Intervention: Delayed-release mesalamine 2.4 g/day
Number of subjects: 772
Study 17320345 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5mg
Number of subjects: 144
Study 17320345 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.75mg
Number of subjects: 144
Study 17320345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 16494585 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 1429
Study 16494585 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 1429
Study 16494585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1429
Study 16494585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (COX-2 inhibitors)
Number of subjects: 1429
Study 16494585 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg (COX-2 inhibitors)
Number of subjects: 1429
Study 16494585 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg (COX-2 inhibitors)
Number of subjects: 1429
Study 12916644 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouping on the left side of the display
Number of subjects: 8
Study 12916644 — intervention group
Group type: COMPARATOR
Intervention: Empty left page (control)
Number of subjects: 8
Study 11180418 — intervention group
Group type: EXPERIMENTAL
Intervention: Court appointed expert siding with the plaintiff
Number of subjects: 0
Study 11180418 — intervention group
Group type: EXPERIMENTAL
Intervention: Court appointed expert siding with the defendant
Number of subjects: 0
Study 11180418 — intervention group
Group type: COMPARATOR
Intervention: Medical testimony provided by experts hired by each side (plaintiff and defendant)
Number of subjects: 0
Study 8815124 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque reduction assay
Number of subjects: 0
Study 8815124 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay-based neutralization assay
Number of subjects: 0
Study 1510237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat extracts (active IT)
Number of subjects: 24
Study 1510237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog extracts (active IT)
Number of subjects: 24
Study 1510237 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 24
Study 6145639 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 (PGE2)
Number of subjects: 200
Study 6145639 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of oxytocin (Oxy)
Number of subjects: 200
Study 29132179 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 24
Study 29132179 — intervention group
Group type: EXPERIMENTAL
Intervention: nHFT
Number of subjects: 24
Study 28605119 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage three times per week for 4 weeks
Number of subjects: 46
Study 28605119 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 46
Study 25496023 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU retinyl palmitate daily for 4 months)
Number of subjects: 31
Study 25496023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 pearl per day for 4 months)
Number of subjects: 31
Study 25496023 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no supplementation)
Number of subjects: 31
Study 23127418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheating condition (language focused on the action: 'Please don't cheat')
Number of subjects: 3
Study 23127418 — intervention group
Group type: COMPARATOR
Intervention: Cheater condition (language highlighting implications for identity: 'Please don't be a cheater')
Number of subjects: 3
Study 21809148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg bolus
Number of subjects: 40
Study 21809148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40
Study 18507542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 89
Study 18507542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 16882622 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with a mean dose of 32 Gy (range 30 - 46 Gy)
Number of subjects: 46
Study 16882622 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with doses of 35 - 46 Gy
Number of subjects: 46
Study 15310395 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid training course
Number of subjects: 301
Study 15310395 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed group
Number of subjects: 301
Study 11329782 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin 30 mg/day
Number of subjects: 63
Study 11329782 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin 60 mg/day
Number of subjects: 63
Study 11329782 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin 90 mg/day
Number of subjects: 63
Study 11329782 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin 120 mg/day
Number of subjects: 63
Study 9042095 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable angina pectoris patients
Number of subjects: 809
Study 9042095 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients with stable angina pectoris
Number of subjects: 809
Study 9042095 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 809
Study 8302687 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule (reference)
Number of subjects: 24
Study 8302687 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution under fasting conditions
Number of subjects: 24
Study 8302687 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution mixed with orange juice
Number of subjects: 24
Study 3090588 — intervention group
Group type: EXPERIMENTAL
Intervention: beta blocker (atenolol or propranolol)
Number of subjects: 26
Study 3090588 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 31695136 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 100
Study 31695136 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil citrate (SC)
Number of subjects: 100
Study 28474088 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg IV dexamethasone
Number of subjects: 108
Study 28474088 — intervention group
Group type: COMPARATOR
Intervention: IV isotonic saline
Number of subjects: 108
Study 27321368 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g ACCS100 daily for 3 months
Number of subjects: 234
Study 27321368 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g ACCS100 daily for 3 months
Number of subjects: 234
Study 27321368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 24730717 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lithium carbonate for 4 years
Number of subjects: 19
Study 24730717 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (n = 7)
Number of subjects: 19
Study 20363158 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist extension splint (Group I, 24 elbows)
Number of subjects: 42
Study 20363158 — intervention group
Group type: COMPARATOR
Intervention: Counterforce forearm strap (Group II, 20 elbows)
Number of subjects: 42
Study 17367559 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic radical antrectomy
Number of subjects: 119
Study 17367559 — intervention group
Group type: COMPARATOR
Intervention: Classical endoscopic middle meatal antrostomy
Number of subjects: 119
Study 16402607 — intervention group
Group type: EXPERIMENTAL
Intervention: Age induced alterations in heart rate dynamics
Number of subjects: 0
Study 16402607 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging relative dynamic dominance of the parasympathetic nervous system function
Number of subjects: 0
Study 16402607 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed concept of 'autonomic aging'
Number of subjects: 0
Study 12874694 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-port laparoscopic cholecystectomy
Number of subjects: 120
Study 12874694 — intervention group
Group type: COMPARATOR
Intervention: Four-port laparoscopic cholecystectomy
Number of subjects: 120
Study 10801752 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stable ST-segment recovery (50% ST-segment recovery sustained for >4 hours with <100 microV change in the peak lead)
Number of subjects: 134